As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran
US Decision Expected Before 2020 Ends
Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.
You may also be interested in...
US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
EMA: Moment Of Truth For Two Curative Therapies & A Possible Cholesterol-Lowering Blockbuster
The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.